 |
 |
|
 |
I. Multiplex PCR
A multiplexed PCR reaction is performed to amplify the regions of interest in the target human or infectious agent genes. |
|
 |
|
|
II. Exo/SAP treatment of PCR Product
The PCR reaction is treated to remove excess nucleotides and primers.
|
|
|
|
 |
III. Multiplex ASPE/TSPE
The PCR reaction is then subjected to a primer extension step that is specific for the allele or the infectious agent that is being analyzed (Allele Specific Primer Extension (ASPE) or Target Specific Primer Extension (TSPE)). The 5’ end of the ASPE or TSPE primers is attached to an xTAG universal tag sequence.
|
|
|
|
 |
IV. Universal Array Sorting
The 5’ universal tag sequence is hybridized to the complementary anti-tag sequence coupled to a particular xMAP bead set.
|
|
|
|
| Wash (Remove in Streamlined) |
|
 |
V. Detection
The hybridized beads are read by the Luminex System and results are analyzed by the data analysis software.
|
|
|
|
| Luminex System Detection |
|
|
|
 |
|
|
Luminex xTAG™ products provide accurate, flexible, low cost microarrays, combining any set of 100 single DNA tests and multiplexing them simultaneously in a single reaction. xTAG products are conducted on the Luminex xMAP® system, which uses lasers to read color-coded microspheres that attach to specific nucleic acid sequences. xTAG was formerly known as TAG-IT from TmBioscience.
|
|
|
|
Description
|
Catalog Number
|
Samples Tested
|
Targets Assay is Designed to Detect
|
|
CFTR IVD
|
I006C0068 (USA)
|
96
|
More information
|
|
I006C0071 (outside USA)
|
96
|
|
| xTAG RVP* |
I019C0111 (USA) |
96 |
More information |
|
I019C0115 (outside USA) |
96 |
|
| *CE marked in Europe. Available as IUO elsewhere. Contact Luminex for more information. |
|
|
Description
|
Catalog Number
|
Samples Tested
|
Targets Assay is Designed to Detect
|
|
Ashkenazi Jewish Panel*
|
R010A0040
|
24
|
More information
|
|
CFTR 70+6*
|
R015C0074
|
96
|
More information
|
|
Coagulation panel*
|
R003A0007
|
24
|
More information
|
|
P450-2C19*
|
R018A0102
|
24
|
More information
|
|
P450-2D6*
|
R016A0096
|
24
|
More information
|
|
P450-2C9 + VKORC1*
|
R021A0112
|
24
|
More information |
|
* For Investigational Use Only. The performance characteristics of this product have not been established.
|
|
|
|
 |
|
| Disease |
Gene |
Mutation/Polymorphism(s) |
|
Tay-Sachs Disease
|
HEXA
|
Δ7.6kb**, R247W*, R249W*, G269S, IVS9(+1)G>A**, 1278insTATC, IVS12(+1)G>C
|
|
Canavan Disease
|
ASPA
|
433(-2)A>G, Y231X(C>A & C>T*), E285A, A305E
|
|
Familial Dysautonomia
|
IKBKAP
|
R696P, IVS20(+6)T>C
|
|
Gaucher Disease
|
GBA
|
84G>GG, IVS2(+1)G>A, N370S, Δ55bp, V394L, D409H**, L444P, R496H
|
|
Bloom’s Syndrome
|
BLM
|
2281del6/ins7
|
|
Fanconi Anemia GrpC
|
FANCC
|
322delG, IVS4(+4)A>T
|
|
Niemann-Pick
|
SMPD1
|
L302P, 1bp del P330fs, R496L, DR608
|
|
Mucolipidosis Type IV
|
MCOLN1
|
Δ6.4kb, IVS3(-2)A>G
|
|
|
|
|
|
 |
|
| Mutations/Polymorphisms |
|
|
|
|
DF508
|
R1162X
|
V520F
|
R1066C
|
|
DI507
|
3849+10kbC>T
|
A559T
|
W1089X |
|
G542X
|
W1282X
|
S549N
|
D1152H
|
|
G85E
|
N1303K
|
S549R (T>G) |
R1158X
|
|
R117H
|
E60X
|
G622D
|
3791delC
|
|
621+1G>T
|
R75X
|
1078delT
|
S1196X
|
|
711+1G>T
|
405+3A>C
|
1677delTA
|
2183AA>G
|
|
R334W
|
406-1G>A
|
1812-1G>A
|
2307insA
|
|
R347P
|
444delA
|
1898+5G>T
|
Y1092X
|
|
3659delC
|
R117C
|
2055del9>A
|
M1101K
|
|
A455E
|
G178R
|
2143delT
|
S1255X
|
|
1717-1G>A
|
L206W
|
K710X
|
3876delA
|
|
R560T
|
935delA
|
Q890X
|
3905insT
|
|
R553X
|
DF311
|
2869insG
|
I148T
|
|
G551D
|
G330X
|
3120G>A
|
D1270N
|
|
1898+1G>A
|
R352Q
|
394delTT |
5/7/9T
|
|
2184delA
|
S364P
|
Y122X
|
F508C
|
|
2789+5G>A
|
G480C
|
R347H
|
I507V
|
|
3120+1G>A
|
Q493X
|
3199del6
|
I506V
|
|
|
|
|
 |
|
| Targets |
| Factor V |
| Factor II |
| MTHFR677 |
| MTHFR1298 |
|
|
|
 |
|
| Variant † |
Major Allele |
|
681G>A
|
CYP2C19*2 (A,B)
|
|
636G>A
|
CYP2C19*3
|
|
1A>G
|
CYP2C19*4
|
|
1297C>T
|
CYP2C19*5 (A,B)
|
|
395G>A
|
CYP2C19*6
|
|
IVS5+2T>A
|
CYP2C19*7
|
|
358T>C
|
CYP2C19*8
|
|
|
|
|
|
|
|
 |
|
| Variant † |
Major Allele |
| / |
Gene Duplication
|
| / |
*5
|
|
-1584C>G
|
*2A Promoter
|
|
100C>T
|
*4(A-L), *10(A,B)
|
|
124G>A
|
*12 |
|
883G>C
|
*11 |
|
1023C>T
|
*17 |
|
T1707T>del
|
*6(A-D)
|
|
1758G>T
|
*8
|
|
1846G>A
|
*4(A-L)
|
|
2549A>del
|
*3(A,B)
|
|
2613-2615
delAGA
|
*9
|
|
2850C>T
|
*2,*17
|
|
2935A>C
|
*7 |
|
|
|
|
|
P450-2C9+VKORC1
|
|
|
| Variant |
Nucleotide Change |
| CYP2C9*1 |
None |
| CYP2C9*2 |
430 C → T |
| CYP2C9*3 |
1075 A → C |
| CYP2C9*4 |
1076 T → C |
| CYP2C9*5 |
1080 C → G |
| CYP2C9*6 |
818delA |
| VKORC1-1639 |
-1639 G → A |
| VKORC1+85 |
85 G → T |
| VKORC1+121 |
121 G → T |
| VKORC1+134 |
134 T → C |
| VKORC1+172 |
172 A → G |
| VKORC1+1331 |
1331 G → A |
| VKORC1+3487 |
3487 T → G |
|
|
|
|
|
|
